Chronic Cannabis Smoking, Oxidative Stress and the Pulmonary Innate Immune Response

Recruiting now

Conditions studied: Cannabis Smoking, Oxidative Stress

In brief

This study plans to evaluate the effects of chronic cannabis smoking on lung health by evaluating its effects on pulmonary health, lung physiology and alveolar macrophage function.

Key facts

Study ID

NCT02480283

Run by

University of Colorado, Denver

People needed

100

Starts

2015-11-11

Expected to finish

2027-07-01

Last updated by the study team

2024-10-10

Who can join

Age: 18 and older, up to 55. Sex: any. Healthy volunteers: accepted.

You may qualify if…

• INCLUSION CRITERIA for CANNABIS USING patient: Subjects will be eligible if they meet ALL of the following criteria:
• Daily or near daily cannabis use (inhaled via joint/cigarette or pipe) equivalent to AT LEAST 20 "joint years" (number of joints/cigarettes per day multiplied by number of years during which cannabis was smoked) by self-report and validated through urine drug screen.
• Never or limited exposure to inhaled tobacco products (equivalent to LESS THAN one "pack year" in a lifetime) by selfreport and validated through negative urine cotinine screen.
• Capacity to answer screening questions and provide informed consent at time of interview, along with contact information
• INCLUSION CRITERIA for CONTROL patient: Subjects will be eligible if they meet all of the following:
• No cannabis use ever by self-report, and validated through urine drug screen.
• Never users of tobacco/cigarettes
• Capacity to answer screening questions and provide informed consent at time of interview, along with contact information.

You may not qualify if…

• EXCLUSION CRITERIA for CANNABIS USING patient: Subjects will be ineligible if they meet ANY of the following criteria:
• LESS THAN near daily cannabis use (inhaled via joint/cigarette or pipe) equivalent to LESS THAN 20 "joint years" (number of joints/cigarettes per day multiplied by number of years during which cannabis was smoked) or a negative urine drug screen (for cannabis)
• Inhaled tobacco product exposure EXCEEDING one "pack year" or a positive urine cotinine screen
• Elevated AUDIT-C score: A 3 item questionnaire to identify subjects with alcohol use disorders.
• Prior medical history of liver disease: cirrhosis, total bilirubin > 2.0 mg/dL or albumin <3
• Prior medical history of myocardial infarction or congestive heart failure
• Prior medical history of end-stage renal disease or serum creatinine >3 mg/dL
• Prior history of or current use of illicit drug use defined as a positive toxicology screen for opiates or cocaine
• Prior history of diabetes mellitus
• Prior history of chronic obstructive pulmonary disease (COPD) or asthma that is not clinically controlled (have not required systemic corticosteroids in the past month)
• Prior history of HIV, not controlled or on medication
• Peripheral white blood cell count of less than 3000
• Acute worsening (<7 days) in respiratory symptoms (such as change in cough frequency or sputum production, fever, dyspnea, abnormal chest radiograph), or room air pulse oximetry of < 92% at rest or spirometry of < 50% predicted for FEV1 and FVC
• Use of systemic antibiotics for any reason in the past month (4 weeks)
• Failure of a subject or the subject's substance abuse counselor to provide assent
• Nutritional risk index of less than 95
• Age < 21 or > 55 (using an age of 55 limits the likelihood of comorbid conditions that may increase the risk of adverse events with bronchoscopy)
• Pregnancy
• Decisionally challenged
• Prisoners.
• EXCLUSION CRITERIA for CONTROL patient: Subjects will be ineligible to participate if they meet ANY of the following criteria:
• History of inhaled cannabis exposure EXCEEDING one "joint year" or positive urine toxicology screen (for cannabis)
• History of inhaled tobacco product exposure EXCEEDING one "pack year" or a positive urine cotinine screen
• Elevated AUDIT-C score: A 3 item questionnaire to identify subjects with alcohol use disorders.
• Prior medical history of liver disease: cirrhosis, total bilirubin > 2.0 mg/dL or albumin <3

Where it is running

• University of Colorado, Denver — Aurora, Colorado, United States (enrolling)

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.